74 related articles for article (PubMed ID: 16173040)
1. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].
Szepeshazi K; Schally AV; Keller G; Block NL; Benten D; Halmos G; Szalontay L; Vidaurre I; Jaszberenyi M; Rick FG
Oncotarget; 2012 Jul; 3(7):686-99. PubMed ID: 22824624
[TBL] [Abstract][Full Text] [Related]
2. Luteinizing hormone releasing hormone-RNase A conjugates specifically inhibit the proliferation of LHRH-receptor-positive human prostate and breast tumor cells.
Gho YS; Chae CB
Mol Cells; 1999 Feb; 9(1):31-6. PubMed ID: 10102568
[TBL] [Abstract][Full Text] [Related]
3. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer.
Boxer RS; Kenny AM; Dowsett R; Taxel P
Aging Male; 2005; 8(3-4):207-12. PubMed ID: 16390748
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.
Dharap SS; Wang Y; Chandna P; Khandare JJ; Qiu B; Gunaseelan S; Sinko PJ; Stein S; Farmanfarmaian A; Minko T
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12962-7. PubMed ID: 16123131
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic activity and cell specificity of a novel LHRH peptide drug conjugate, D-Cys6-LHRH vedotin, against ovarian cancer cell lines.
Vankadara S; Ke Z; Wang S; Foo SY; Gunaratne J; Lee MA; Koh X; Chia CSB
Chem Biol Drug Des; 2024 Apr; 103(4):e14516. PubMed ID: 38618710
[TBL] [Abstract][Full Text] [Related]
6. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.
True LD; Buhler K; Quinn J; Williams E; Nelson PS; Clegg N; Macoska JA; Norwood T; Liu A; Ellis W; Lange P; Vessella R
Am J Pathol; 2002 Aug; 161(2):705-15. PubMed ID: 12163395
[TBL] [Abstract][Full Text] [Related]
7. New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.
Schally AV; Block NL; Rick FG
Asian J Androl; 2015; 17(6):925-8. PubMed ID: 26112478
[TBL] [Abstract][Full Text] [Related]
8. Serially heterotransplanted human prostate tumours as an experimental model.
Lopez-Barcons LA
J Cell Mol Med; 2010 Jun; 14(6B):1385-95. PubMed ID: 19874422
[TBL] [Abstract][Full Text] [Related]
9. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
12. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
13. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Nagy A; Schally AV
Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
[TBL] [Abstract][Full Text] [Related]
14. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Bajo AM; Schally AV; Halmos G; Nagy A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
